Journal of International Psychiatry

Abstract Objective: To investigate the effect of risperidone and aripiprazole on the clinical efficacy and glucose/lipid metabolism in the treatment of Alzheimer disease with mental disorders. Methods: A total of 128 patients of Alzheimer disease with mental disorders in our hospital from Jan. 2014 to Dec. 2015 were enrolled in the study, which were randomly divided into risperidone group (63 cases) and aripiprazole group (65 cases). The risperidone group were received 2-4mg risperidone oral, qn, and the aripiprazole group were received 10-20mg aripiprazole oral, qn. The easy-mental state table (MMSE) score, Alzheimer disease assessment form- cognitive subscale (ADAS-cog) score and glucose/lipid metabolism indexes were determined before and after 3 month treatment. Results: After treatment, the MMSE scores in risperidone group and aripiprazole group were significantly increased (p<0.05), and the ADAS-cog scores in the two groups were significantly decreased (p<0.05). There was no statistical difference between the two groups (p>0.05). After treatment, the blood glucose in risperidone group was significantly increased (p<0.05), but no statistical difference in aripiprazole group (p>0.05), and the blood glucose in risperidone group was significantly higher than that in aripiprazole group (p>0.05). After treatment, the tota cholesterol and triglyceride in risperidone group and aripiprazole group were significantly increased (p<0.05), and the tota cholesterol and triglyceride in risperidone group was significantly higher than that in aripiprazole group (p>0.05). Conclusion: Risperidone and aripiprazole could be used for the treatment of Alzheimer disease with mental disorders. They both caused abnormal glucose and lipid metabolism, and the effect of aripiprazole was relatively mild.

Keywords: Risperidone, Aripiprazole, Alzheimer disease, Mental disorders, Glucose/lipid metabolism